Kangmei Pharmaceutical Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 2,352.44 million compared to CNY 1,767.19 million a year ago. Revenue was CNY 2,377 million compared to CNY 1,778.87 million a year ago.

Net loss was CNY 125.86 million compared to CNY 195.65 million a year ago. Basic loss per share from continuing operations was CNY 0.009 compared to CNY 0.014 a year ago. Diluted loss per share from continuing operations was CNY 0.009 compared to CNY 0.014 a year ago.